You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 20, May 28, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Medical Practice
 •Law and Medicine
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Humanities
 •Medicine and the Media
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Liability for Adverse Events in Direct-to-Consumer Advertising—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Shein highlights the complexity of DTCA's impact on public health and hence the difficulty of crafting an appropriate regulatory and legal response. In particular, there is substantial face validity to his concern that advertisements can mislead patients or subtly alter their preferences in ways that cannot be overcome through subsequent discussions with their intermediaries. There is ample reason to closely monitor changes in physicians' ability to steer patients to appropriate treatments and to reconsider the learned intermediary rule if future studies demonstrate that the assumptions on which it is based are no longer true.

Many of Shein's concerns, however, are not well addressed by a change in failure-to-warn doctrine. They go to the more fundamental issue of whether DTCA should be permitted at all—a question, as we noted, that has constitutional implications. We share Shein's concern about misleading advertisements, but that problem is more readily remediable through . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Liability for Adverse Events in Direct-to-Consumer Advertising
David Shein
JAMA. 2003;289(20):2646.
EXTRACT | FULL TEXT  

Liability for Adverse Events in Direct-to-Consumer Advertising
George W. Evans and Arnold I. Friede
JAMA. 2003;289(20):2646-2647.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.